Hyperion DeFi’s (HYPD) Sell (D-) Rating Reiterated at Weiss Ratings

Hyperion DeFi (NASDAQ:HYPD)‘s stock had its “sell (d-)” rating reiterated by equities research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen downgraded shares of Hyperion DeFi from a “hold” rating to a “sell” rating in a research note on Saturday, July 26th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $2.00.

Hyperion DeFi Price Performance

Shares of NASDAQ HYPD opened at $9.06 on Wednesday. Hyperion DeFi has a fifty-two week low of $0.85 and a fifty-two week high of $47.33. The company has a 50 day simple moving average of $8.36 and a two-hundred day simple moving average of $5.96. The company has a market capitalization of $63.06 million, a price-to-earnings ratio of -0.16 and a beta of 2.57. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.91 and a current ratio of 0.91.

Hyperion DeFi (NASDAQ:HYPD) last announced its earnings results on Wednesday, August 13th. The company reported ($2.50) earnings per share for the quarter. Hyperion DeFi had a negative net margin of 62,238.41% and a negative return on equity of 876.25%. Analysts expect that Hyperion DeFi will post -41.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Hyperion DeFi

An institutional investor recently bought a new position in Hyperion DeFi stock. Virtu Financial LLC purchased a new stake in shares of Hyperion DeFi, Inc. (NASDAQ:HYPD) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 23,065 shares of the company’s stock, valued at approximately $25,000. Virtu Financial LLC owned about 0.82% of Hyperion DeFi as of its most recent SEC filing. 25.84% of the stock is currently owned by institutional investors and hedge funds.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.